Home/Pipeline/VOR33

VOR33

Acute Myeloid Leukemia (AML)

Phase 1/2Active

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

Phase 1/2

Status

Active

Company

PureTech Health

About PureTech Health

PureTech Health is a Boston-based biotech studio that creates and funds separate companies around innovative scientific discoveries, de-risking development and capturing value through equity and royalties. Its model has proven exceptionally successful, boasting a 6x higher clinical success rate than the industry average and delivering three FDA-approved therapies. The company's strategy leverages a deep network of academic collaborators and seasoned leadership to build a diversified portfolio across immunology, neurology, and gastroenterology.

View full company profile

Therapeutic Areas

Immunology Neurology Gastroenterology Psychiatry Oncology Metabolic Disease

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lomonitinib	Lomond Therapeutics	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
oNKord® (Inaleucel)	Glycostem	Phase 1/2a	Active
M2T™ Program (unspecified)	Leukogene Therapeutics	Preclinical	Active